

## Drug Monograph

Drug/Drug **Doptelet® (avatrombopag maleate) film coated tablet /**  
 Class: **Thrombopoietin Receptor Agonist**  
 Prepared for: MO HealthNet  
 Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Doptelet® is available in a film coated tablet containing 20 mg avatrombopag.

**Manufacturer:** Manufactured for: AkaRx, Inc., Durham, NC 27707

**Indications:** Doptelet® is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

**Costs:** \$940.22 per tablet of Doptelet® Maximum Allowable Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Preferred  
 Appropriate Indications  Under Solicitation

Prepared By: Luke Boehmer PharmD  
 Date: November 30, 2018